University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial Search: "Breast"



Treatment trials which apply specifically to your search:


0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-14-2

Trial Leaders:
David Quinn

An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (Egfr, Her2, Her3) Mutations or EGFR Gene Amplification

Treatment:
Chemotherapy: Systemic

0C-15-2

Trial Leaders:
Barbara Gitlitz

STARTRK-2 (Studies of Tumor Alterations Responsive to Targeting Receptor Kinases-2) An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Treatment:
Chemotherapy: Systemic

0C-15-3

Trial Leaders:
Anthony El-Khoueiry

PhI-76 Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed

Treatment:
Chemotherapy: Systemic

0C-15-5

Trial Leaders:
Anthony El-Khoueiry

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

Treatment:
Chemotherapy: Systemic

0C-16-2

Trial Leaders:
Heinz Josef Lenz

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

0S-08-9

Trial Leaders:
Tanya Dorff

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-10-3

Trial Leaders:
Tanya Dorff

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy.

Treatment:
Other

0S-14-3

Trial Leaders:
Syma Iqbal

Phase II Study of Single Agent Regorafenib in Patients with Advanced/Metastatic Neuroendocrine Tumors

Treatment:
Chemotherapy: Systemic

0S-14-9

Trial Leaders:
Heinz Josef Lenz

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination with Nivolumab in Select Advanced Cancers

Treatment:
Chemotherapy: Systemic
Immunotherapy

1B-10-3

Trial Leaders:
Julie Lang

Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2.

Treatment:
Chemotherapy: Systemic

1B-12-1

Trial Leaders:
Christina M. Dieli-Conwright

Combined Exercise Program for Early Breast Cancer Survivors.

Treatment:
(No treatments specified)

1B-12-10

Trial Leaders:
Darcy Spicer

Phase II Trial of Metronomic Capecitabine and Cyclophosphamide with Lapatinib and Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen.

Treatment:
Chemotherapy: Systemic
Immunomodulator

1B-13-1

Trial Leaders:
Christy Russell

A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

Treatment:
Chemotherapy: Systemic

1B-13-10

Trial Leaders:
Darcy Spicer

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer. (The “METRIC” Study)

Treatment:
Chemotherapy: Systemic

1B-13-11

Trial Leaders:
Christy Russell

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician’s Choice In Previously-Treated, HER2 Negative, Germline BRCA Mutation-Positive Breast Cancer Patients (BRAVO)

Treatment:
Chemotherapy: Systemic

1B-14-5

Trial Leaders:
Christina M. Dieli-Conwright

High-intensity Interval training (HIT) for Breast Cancer Patients during Trastuzumab Use

Treatment:
Other

1B-14-7

Trial Leaders:
Heather R. Macdonald

Breast Cancer Patient Navigation and Tailored Treatment Planning: A Process Evaluation Study for LAC+USC Patient Navigation, Treatment Planning, and Ongoing Support for Latina Women

Treatment:
Other

ctsu/CALGB-A011202

Trial Leaders:
Julie Lang

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

Treatment:
Radiation: External
Surgery

ctsu/NSABP-51/RTOG1304

Trial Leaders:
Naomi Schechter

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Treatment:
Radiation: External

NRG-BR001

Trial Leaders:
Naomi Schechter

A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

Treatment:
Radiation: External

SWOG-S1200

Trial Leaders:
Christy Russell

Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer.

Treatment:
Other

SWOG-S1207

Trial Leaders:
Darcy Spicer

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

Phase I trials for all solid tumors:


0C-11-1

Trial Leaders:
Heinz Josef Lenz

Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction.

Treatment:
Chemotherapy: Systemic

0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-12-3

Trial Leaders:
Heinz Josef Lenz

Phase I Trial of Oral 5-Fluoro-2’-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-13-1

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Parallel-Group, Multi-Center Phase I Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Hepatic Impairment.

Treatment:
Chemotherapy: Systemic

0C-13-6

Trial Leaders:
Heinz Josef Lenz

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 In Combination with Capecitabine in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-14-10

Trial Leaders:
Anthony El-Khoueiry

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Local

0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-15-3

Trial Leaders:
Anthony El-Khoueiry

PhI-76 Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed

Treatment:
Chemotherapy: Systemic

0C-15-4

Trial Leaders:
Anthony El-Khoueiry

A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

Treatment:
Immunotherapy

0C-16-1

Trial Leaders:
Anthony El-Khoueiry

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB™ FS102 in HER2 positive Solid Tumors

Treatment:
Other

0C-16-2

Trial Leaders:
Heinz Josef Lenz

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

0C-16-3

Trial Leaders:
Heinz Josef Lenz

An Open-Label, Non-Randomized, Multicenter Phase I Study to Determine the Maximum Tolerated or Recommended Phase II Dose of Oral Mutant IDH1 Inhibitor BAY 1436032 and to Characterize its Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic and Anti-Tumor Activity in Patients with IDH1-R132X-Mutant Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0S-08-9

Trial Leaders:
Tanya Dorff

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-14-9

Trial Leaders:
Heinz Josef Lenz

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination with Nivolumab in Select Advanced Cancers

Treatment:
Chemotherapy: Systemic
Immunotherapy

0S-15-13

Trial Leaders:
Caroline Piatek

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism

Treatment:
Other

Trials which are NOT treatments of disease. Specimens or information may be collected:


0S-00-16

Trial Leaders:
Heinz Josef Lenz

Molecular Determinants of Response and Survival to Platinum Compounds (Oxaliplatin and Cisplatin) in Patients with Cancer.


0S-04-7

Trial Leaders:
Michael Press

USC Tumor and Tissue Bank.


0S-08-5

Trial Leaders:
Darcy Spicer

Multi-Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer – A Lynne Cohen Consortium Project.


0S-10-1

Trial Leaders:
Florence Wong

A Survey of Complementary and Alternative Medicine (CAM) Use and Interest to Participate in CAM Research Studies in a Comprehensive Cancer Center.


0S-11-5

Trial Leaders:
Amir Goldkorn

Circulating Tumor Cell Collection from Cancer Patients.


0S-12-4

Trial Leaders:
Stephen Gruber

USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.


0S-13-1

Trial Leaders:
Gregory Idos

USC Norris Comprehensive Cancer Center and Stanford Cancer Institute Cancer Genetics Hereditary Cancer Panel Testing


0S-15-12

Trial Leaders:
Stephen Gruber

Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership with Patients.


0S-15-13

Trial Leaders:
Caroline Piatek

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism


0S-15-15

Trial Leaders:
Patrick Williams

Are Last Impressions Lasting Impressions? Intervention of Ringing a Bell at the End of Cancer Treatment


0S-15-17

Trial Leaders:
Patrick Williams

Patient Perceptions of Side Effects of Cancer Chemoradiotherapy


0S-15-9

Trial Leaders:
Heinz Josef Lenz

PhI-78, Patient-Derived Models Tissue Procurement Protocol For The National Cancer Institute (NCI)


0S-16-2

Trial Leaders:
Jorge Nieva

Accelerometry to Optimize and Monitor Human Performance in Cancer Chemotherapy Outpatients


0S-16-9

Trial Leaders:
Ebrahim Zandi

The Role of Microbiome in Cancer Therapy


1B-11-1

Trial Leaders:
Julie Lang

Breast Cancer Blood Biorepository.


1B-12-6

Trial Leaders:
Jaques Van Dam

Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study.


1B-12-9

Trial Leaders:
Darcy Spicer

An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with Her2 Positive (Her2+) Metastatic Breast Cancer.


1B-13-2

Trial Leaders:
Julie Lang

Core Biopsies of Breast Tumor Tissue Repository.


1B-14-6

Trial Leaders:
Anna Wu

Changes in Intestinal Microbiota in Association with Chemotherapy Treatment


2N-12-7

Trial Leaders:
Daniel Oh

DNA Methylation Markers for Detecting Cancer Cells in Malignant Pleural Effusion.


3G-07-3

Trial Leaders:
Heinz Josef Lenz

Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.


6CNS-07-1

Trial Leaders:
Thomas Chen

Establishment of USC CNS and Spine Tumor Bank.